FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549	
-------------	------------	--

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cahill Brian Joseph						2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]										tionship of Reporti all applicable) Director Officer (give title		10% O	ner	
(Last)	(Fir	,	/liddle)		3 Da	Date of Earliest Transaction (Month/Day/Year)										ow) Chief Fina	ıncial	below) l Officer		
C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BOULEVARD, SUITE 315						01/05/2022														
(Street)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
WOODO LAKE	CLIFF NJ	0	7677												X Form filed by One Reporting Person					
LAKE																m filed by Mo son	ore tha	an One Rep	orting	
(City)	(St	ate) (2	<u>Z</u> ip)																	
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or	Ben	efici	ally Ow	ned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			y/Year) Exec		Deemed cution Date, ly nth/Day/Year)		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			nd Secu Bene	nount of rities ficially ed Following	Forr (D)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	v	Amount	(A) (D)	or	Price	Trans	action(s) 3 and 4)			(111341.4)				
Common Stock 01/05/					2022				F ⁽¹⁾		738	I)	\$ 5 0.	59 26,361			D		
		Tal									osed of, convertib					ed				
Security or Exercise (Month/Day/Year) if any			emed ion Date, //Day/Year) 4. Transac Code (Ir 8)					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		f g	8. Price o Derivative Security (Instr. 5)		ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nu of	mber ares						

Explanation of Responses:

Remarks:

/s/ Brian Cahill

01/07/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Represents shares withheld to satisfy withholding tax obligations.